FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 97 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR Cancer Research UK releases 2022 gender and ethnicity pay gap reports March 23, 2023 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ January 17, 2022 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment September 24, 2021 Load more HOT NEWS Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer Shannen Doherty Opens Up About Life After Cancer And BH90210 Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... ΠΟΝΟΣ
